Value of Onconeural Antibodies in Checkpoint Inhibitor‐Related Toxicities
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Neurology"
DOI: 10.1002/ana.25764
Abstract: Value of Onconeural Antibodies in Checkpoint Inhibitor-Related Toxicities Alberto Vogrig, MD , Sergio Muñiz-Castrillo, MD , and Jérôme Honnorat, MD, PhD An increasing number of patients will be exposed to immune checkpoint inhibitors (ICIs) in… read more here.
Keywords: related toxicities; onconeural antibodies; antibodies checkpoint; value onconeural ... See more keywords
Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Molecular Diagnostics"
DOI: 10.1080/14737159.2018.1440209
Abstract: ABSTRACT Introduction: Immune checkpoint pathways are key immune regulatory pathways that play a physiologic role in maintaining immune-homeostasis and are often co-opted by cancer cells to evade the host immune system. Recent developments in cancer… read more here.
Keywords: related toxicities; biomarkers immune; current progress; immune related ... See more keywords
MBCL-23. PRELIMINARY ANALYSIS OF TREATMENT-RELATED TOXICITIES DURING INDUCTION CHEMOTHERAPY FOR PATIENTS ON THE HEAD START 4 TRIAL
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.499
Abstract: Abstract The currently active, prospective multi-center Head Start 4 (HS4) trial for CNS embryonal tumors differs from prior HS I-III trials by utilizing absolute phagocyte count (APC) as a measure of myeloid recovery instead of… read more here.
Keywords: related toxicities; head start; treatment related; induction chemotherapy ... See more keywords
Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?
Sign Up to like & getrecommendations! Published in 2022 at "Hematology/oncology and stem cell therapy"
DOI: 10.56875/2589-0646.1029
Abstract: Chimeric antigen receptor T cell (CAR-T) therapy is an immunotherapy, which represents a therapeutic breakthrough in the treatment of B-cell malignancies and multiple myeloma. Since the first CAR T-cell approval in 2017, there have been… read more here.
Keywords: cell; related toxicities; therapy; car ... See more keywords
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2022.0020
Abstract: The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an… read more here.
Keywords: oncology; related toxicities; immunotherapy related; management ... See more keywords